Press releases
MONTDOREX ANNOUNCES ACCEPTANCE OF ITS ABSTRACT FOR PRESENTATION AT THE AACR ANNUAL MEETING 2024
Selected abstract includes preclinical data about MTDX203, a first-in-class, proprietary endo-exonuclease inhibitor with anti-cancer properties
Montreal, Canada, March 7, 2024 (BusinessWire)– Montdorex Inc. (“Montdorex” or “the Company”), a privately-owned precision medicine company, today announced that Terry Chow, Ph.D., Founder and CEO will present insights on the relevance of inhibiting the endo-exonuclease (EE) enzyme in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, to be held in San Diego, CA, April 5 -10, 2024.
The endo-exonuclease enzyme plays a key role in DNA damage repair mechanisms, but it is also overexpressed in cancer tumors. In a proof-of-concept study, Montdorex showed that tumors with increased EE expression showed the best response to pentamidine, an endo-exonuclease inhibitor. The Company has also identified mono- and di-amidine analogs of pentamidine that are more effective than the parent drug in both in vitro and in vivo studies.
“Our lead candidate, MTDX203, showed an increased anti-cancer activity with a higher safety index than pentamidine in preclinical animal studies”, said Terry Chow of Montdorex. “I look forward to presenting our detailed findings to the AACR scientific and investor community at the upcoming annual meeting”.
Details of the AACR poster presentation are as follows:
Poster Presentation (#5604): Modulating DNA repair through endo-exonuclease inhibition: a new therapeutic paradigm in oncology [link to the abstract]
Session Category: Molecular/Cellular Biology and Genetics
Session Title: DNA Damage and Repair 2
Session Date and Time: Tuesday, April 9, 2024 1:30 PM – 5:00 PM (PT)
Location: Poster Section 14, Poster Board Number 2
About Montdorex
Based in Montreal, Canada, Montdorex Inc. is a privately-owned, early-stage precision medicine company, targeting the endo-exonuclease (EE) enzyme involved in cancer tumor growth and inflammatory processes. The company is developing proprietary mono-amidine and di-amidine EE inhibitors to modulate DNA repair in oncology and non cytotoxic di-amidine analogs for anti-inflammatory applications, such as gastrointestinal conditions and liver diseases.
Contact
Terry Y-K Chow, Ph.D.
Founder and CEO
